Some "way 316606" Stuff Is Making Headlines Today.

BetaBoy

Experienced Member
My Regimen
Reaction score
480
We don't have "hairloss pathways" we have hair growth pathways and they're being shut down. The main one being the Wnt pathway. There's good evidence to suggest the Wnt pathway is THE pathway when it comes to Androgenetic Alopecia, and that drugs that are capable of upregulating it, by some method of action, will be essentially an "override switch" turning back on all the hair follicle cells that have gone dormant. I think Wnt agonists have by far the most potential compared to any other drug approach being pursued atm.

The problem is you really want to target the pathway specific to the downregulation acting on HF Wnt signaling due to Androgenetic Alopecia, a blanket upregulation of Wnt signalling is not ideal considering over expression of this pathway is implicated with increased cancer risk.
 

Sanchez1234

Experienced Member
Reaction score
311
We don't have "hairloss pathways" we have hair growth pathways and they're being shut down. The main one being the Wnt pathway. There's good evidence to suggest the Wnt pathway is THE pathway when it comes to Androgenetic Alopecia, and that drugs that are capable of upregulating it, by some method of action, will be essentially an "override switch" turning back on all the hair follicle cells that have gone dormant. I think Wnt agonists have by far the most potential compared to any other drug approach being pursued atm.
I hope you are right. How does DHT fit in the WNT theory?
 

bboy

Established Member
My Regimen
Reaction score
186
I hope you are right. How does DHT fit in the WNT theory?
wnt.jpg



wntlegend.jpg
 
Last edited:

baldco

Member
My Regimen
Reaction score
38
That is a great map bboy, However missing is the recently talked about Cxxc5 pathway leading to negative regulation of DVL1 => increased GSK3B. Increased GSK3B lowers ALP and IGF-1 crucial for DP cells to proliferate. I also found interesting again that same pathway would lead to upregulation of AR expression/activity which would continue to make the problem worse. I am not sure what leads to upregulation of Cxxc5(DHT-AR?)
After reading Choi's paper, which btw was particularly well done, I was quite excited for the Tokyo convention. Not sure what become of it.
 

Georgie

Senior Member
My Regimen
Reaction score
2,721
I’m closing the group buy off today. If you haven’t made an order then that’s it. Cheers guys.
 

fuDHTck

Established Member
My Regimen
Reaction score
682

BetaBoy

Experienced Member
My Regimen
Reaction score
480
https://www.theguardian.com/fashion/2018/sep/02/hair-today-gone-tomorrow

"...Hawkshaw is no longer working on the project, but the Italian pharmaceutical company, Giuliani, hopes to take his findings through to clinical trials..."


Small trivia, Giuliani also makes the generic finasteride I use

Would Giuliani even have the capital to undergo the process of acquiring a licence for a drug like WAY-31606, glossing over their current product portfolio doesn't inspire much hope. Seems to me this would be a company that just sit on a patent until one of the big players with the actual means to commercialise like Pfizer, MSD, GSK etc come along and acquire it.
 

alibaba92

Senior Member
My Regimen
Reaction score
638

alibaba92

Senior Member
My Regimen
Reaction score
638
Its being trialed this month, so for us not 10 years

Seriously ? Do you have any source saying that ?, good to hear anyway. Nevertheless, to be honest, they are pretty late as of now since other treatments have already been in phase 2, phase 3 and they are only "gonna" start phase 1. They are very likely to encounter money and delay issue later as the market will shrink when their competitors release the product and investors, even the pharma themselves, may not feel right risking too much for such a small poor market.
 

Sanchez1234

Experienced Member
Reaction score
311
Seriously ? Do you have any source saying that ?, good to hear anyway. Nevertheless, to be honest, they are pretty late as of now since other treatments have already been in phase 2, phase 3 and they are only "gonna" start phase 1. They are very likely to encounter money and delay issue later as the market will shrink when their competitors release the product and investors, even the pharma themselves, may not feel right risking too much for such a small poor market.
Sorry, i meant trialed by members here. So no safety study so far. But we will soon enough if WAY is giving (short term) sides.
 

alibaba92

Senior Member
My Regimen
Reaction score
638
The more companies the better

I am wondering, how would the release of another effective treatment affect others competitors ? Severely such that they may consider dropping the project or none at all ?
 
Top